z-logo
open-access-imgOpen Access
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
Author(s) -
Naris Kitnarong,
Janyawassamon Kittipiriyakul,
Anuwat Jiravarnsirikul
Publication year - 2022
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 2
ISSN - 2629-995X
DOI - 10.33192/smj.2022.4
Subject(s) - medicine , aflibercept , trabeculectomy , ophthalmology , neovascular glaucoma , intraocular pressure , diabetic retinopathy , glaucoma , visual acuity , surgery , diabetes mellitus , bevacizumab , chemotherapy , endocrinology
Objective: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG).Materials and Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed within 2weeks after IVA. Additional PRP, laser suture lysis, subconjunctival 5-fluorouracil injection, and bleb needlingwere performed after TMC if indicated. Best corrected visual acuity (BCVA), intraocular pressure (IOP), surgicalcomplications, and number of anti-glaucoma medications were collected.Results: Five eyes from 5 consecutive patients were included. Two eyes had proliferative diabetic retinopathy (PDR), 2 central retinal vein occlusion, and 1 ocular ischemic syndrome (OIS) (mean initial IOP: 46.8±6.8 mmHg). NVI regression occurred in one eye after PRP alone, and in one eye after PRP and IVA resulting in a good IOP control with topical medical therapy. The other 3 underwent TMC. The preoperative IOP was 34 (OIS), 54 (PDR), and 50 (PDR) mmHg. The 3-month postoperative IOP decreased to 8, 8, and 4 mmHg, respectively, and to 21, 10, and 6 mmHg, respectively, at the last visit. Only the one OIS eye required postoperative topical IOP-lowering medications. Final BCVA was improved, unchanged, and decreased in 2, 2, and 1 eye, respectively. No intraoperative/postoperative complications or NVI recurrence were observed (mean follow-up: 10.7 months).Conclusion: Intravitreal aflibercept was shown to be a potentially effective additional treatment to PRP and TMC in patients with NVG.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here